000177080 001__ 177080
000177080 005__ 20240229133731.0
000177080 0247_ $$2doi$$a10.1007/s11060-021-03867-8
000177080 0247_ $$2pmid$$apmid:34657224
000177080 0247_ $$2ISSN$$a0167-594X
000177080 0247_ $$2ISSN$$a1573-7373
000177080 0247_ $$2altmetric$$aaltmetric:115602136
000177080 037__ $$aDKFZ-2021-02286
000177080 041__ $$aEnglish
000177080 082__ $$a610
000177080 1001_ $$00000-0003-4446-8257$$aAdolph, Jonas E$$b0
000177080 245__ $$aSystemic chemotherapy of pediatric recurrent ependymomas: results from the German HIT-REZ studies.
000177080 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V$$c2021
000177080 3367_ $$2DRIVER$$aarticle
000177080 3367_ $$2DataCite$$aOutput Types/Journal article
000177080 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642494123_12953
000177080 3367_ $$2BibTeX$$aARTICLE
000177080 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000177080 3367_ $$00$$2EndNote$$aJournal Article
000177080 500__ $$a2021 Nov;155(2):193-202
000177080 520__ $$aSurvival in recurrent ependymoma (EPN) depends mainly on the extent of resection achieved. When complete resection is not feasible, chemotherapy is often used to extend progression-free and overall survival. However, no consistent effect of chemotherapy on survival has been found in patients with recurrent EPN.Systemic chemotherapeutic treatment of 138 patients enrolled in the German HIT-REZ-studies was analyzed. Survival depending on the use of chemotherapy, disease-stabilization rates (RR), duration of response (DOR) and time to progression (TTP) were estimated.Median age at first recurrence was 7.6 years (IQR: 4.0-13.6). At first recurrence, median PFS and OS were 15.3 (CI 13.3-20.0) and 36.9 months (CI 29.7-53.4), respectively. The Hazard Ratio for the use of chemotherapy in local recurrences in a time-dependent Cox-regression analysis was 0.99 (CI 0.74-1.33). Evaluable responses for 140 applied chemotherapies were analyzed, of which sirolimus showed the best RR (50%) and longest median TTP [11.51 (CI 3.98; 14.0) months] in nine patients, with the strongest impact found when sirolimus was used as a monotherapy. Seven patients with progression-free survival > 12 months after subtotal/no-resection facilitated by chemotherapy were found. No definitive survival advantage for any drug in a specific molecularly defined EPN type was found.No survival advantage for the general use of chemotherapy in recurrent EPN was found. In cases with incomplete resection, chemotherapy was able to extend survival in individual cases. Sirolimus showed the best RR, DOR and TTP out of all drugs analyzed and may warrant further investigation.
000177080 536__ $$0G:(DE-HGF)POF4-312$$a312 - Funktionelle und strukturelle Genomforschung (POF4-312)$$cPOF4-312$$fPOF IV$$x0
000177080 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000177080 650_7 $$2Other$$aChemotherapy
000177080 650_7 $$2Other$$aChildren
000177080 650_7 $$2Other$$aEpendymoma
000177080 650_7 $$2Other$$aRecurrence
000177080 650_7 $$2Other$$aSirolimus
000177080 7001_ $$00000-0001-5714-007X$$aFleischhack, Gudrun$$b1
000177080 7001_ $$aGaab, Christine$$b2
000177080 7001_ $$aMikasch, Ruth$$b3
000177080 7001_ $$aMynarek, Martin$$b4
000177080 7001_ $$aRutkowski, Stefan$$b5
000177080 7001_ $$00000-0002-8731-1121$$aSchüller, Ulrich$$b6
000177080 7001_ $$0P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aPfister, Stefan M$$b7$$udkfz
000177080 7001_ $$0P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aPajtler, Kristian$$b8$$udkfz
000177080 7001_ $$0P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aMilde, Till$$b9$$udkfz
000177080 7001_ $$0P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aWitt, Olaf$$b10$$udkfz
000177080 7001_ $$aBison, Brigitte$$b11
000177080 7001_ $$aWarmuth-Metz, Monika$$b12
000177080 7001_ $$aKortmann, Rolf-Dieter$$b13
000177080 7001_ $$aDietzsch, Stefan$$b14
000177080 7001_ $$aPietsch, Torsten$$b15
000177080 7001_ $$aTimmermann, Beate$$b16
000177080 7001_ $$00000-0001-8791-9914$$aTippelt, Stephan$$b17
000177080 7001_ $$aHIT-Network, German GPOH$$b18$$eCollaboration Author
000177080 773__ $$0PERI:(DE-600)2007293-4$$a10.1007/s11060-021-03867-8$$n2$$p193-202$$tJournal of neuro-oncology$$v155$$x1573-7373$$y2021
000177080 909CO $$ooai:inrepo02.dkfz.de:177080$$pVDB
000177080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000177080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000177080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0be2f86573954f87e97f8a4dbb05cb0f$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000177080 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)143af26de9d57bf624771616318aaf7c$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000177080 9131_ $$0G:(DE-HGF)POF4-312$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vFunktionelle und strukturelle Genomforschung$$x0
000177080 9141_ $$y2021
000177080 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-01-28$$wger
000177080 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2021-01-28$$wger
000177080 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURO-ONCOL : 2019$$d2021-01-28
000177080 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-01-28
000177080 9201_ $$0I:(DE-He78)B062-20160331$$kB062$$lB062 Pädiatrische Neuroonkologie$$x0
000177080 9201_ $$0I:(DE-He78)B310-20160331$$kB310$$lKKE Pädiatrische Onkologie$$x1
000177080 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000177080 980__ $$ajournal
000177080 980__ $$aVDB
000177080 980__ $$aI:(DE-He78)B062-20160331
000177080 980__ $$aI:(DE-He78)B310-20160331
000177080 980__ $$aI:(DE-He78)HD01-20160331
000177080 980__ $$aUNRESTRICTED